Stephanie Shibata, PA
Physician Assistant · Las Vegas, NVNPI 1366863953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 338 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Viiv Healthcare Company at 25.7% of the total. Reporting peaked in 2022 at $3,321 and has fallen 90.4% since, to $318 in 2025. Among physician assistant clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Paratek Pharmaceuticals, Inc.$816
- Melinta Therapeutics, LLC$719
- Gilead$704
- Cipla USA Inc.$690
- Merck$550
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,65696%
- Education$3424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 104 | $2,055 |
| Paratek Pharmaceuticals, Inc. | 53 | $816 |
| Melinta Therapeutics, LLC | 24 | $719 |
| Gilead | 30 | $704 |
| Cipla USA Inc. | 4 | $690 |
| Merck | 29 | $550 |
| AbbVie | 20 | $475 |
| Astellas Pharma US Inc | 12 | $338 |
| EMD Serono, Inc. | 8 | $279 |
| Johnson & Johnson(2 entities) | 15 | $245 |
| Shionogi Inc | 7 | $238 |
| Insmed, Inc. | 7 | $133 |
| Amgen | 1 | $125 |
| Janssen Products, LP | 1 | $100 |
| Advanced Respiratory, Inc | 1 | $59 |
| UCB, Inc. | 2 | $57 |
| Cumberland Pharmaceuticals, Inc. | 3 | $56 |
| Baxter Healthcare | 1 | $50 |
| Philips North America LLC | 2 | $47 |
| Boehringer Ingelheim | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Genentech USA, Inc. | 1 | $25 |
| Lilly USA, LLC | 2 | $25 |
| GSK | 2 | $24 |
| La Jolla Pharmaceutical Company | 1 | $23 |
| Theratechnologies Inc. | 1 | $22 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Napo Pharmaceuticals Inc | 1 | $16 |
| KCI USA, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,998 in reported general payments places this provider in the 90th percentile of 881 physician assistant providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 53 | $95,157 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 17 | $68,131 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $62,660 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $50,287 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $49,276 |
| IsentressRaltegravir Potassium | 11 | $21,885 |
| ErtapenemErtapenem Sodium | 21 | $10,270 |
| Fosfomycin Tromethamine | 23 | $5,708 |
| Cefepime Hcl | 34 | $4,636 |
| Meropenem | 13 | $2,282 |
| Doxycycline Hyclate | 58 | $1,921 |
| Ethambutol Hcl | 32 | $1,916 |
| Vancomycin Hcl | 17 | $1,264 |
| Methenamine Hippurate | 19 | $1,170 |
| Cefdinir | 29 | $951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $704 | $99,56325 claims |
| Viiv Healthcare CompanyDovato | $2,055 | $62,66021 claims |
| MerckIsentress | $550 | $21,88511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 881 physician assistant providers in Nevada.
Other physician assistant in Las Vegas
- Steven HawkesLas Vegas$70K
- Nathan MorganLas Vegas$44K
- Stephanie DastrupLas Vegas$23K
- Sandra OviedoLas Vegas$21K
- Patrick JamesonLas Vegas$20K
- Jordan ChristensenLas Vegas$19K
- Jacquelyn DaneshforouzLas Vegas$18K
- Violet AmirjalaliLas Vegas$15K
- Joseph GuruleLas Vegas$15K
- Rebecca Markin-NewsomeLas Vegas$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.